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Many assays for enzymes and metabolites of collagen metabolism have been investigated 
in serum to assess fibrogenesis， fibrolysis and fibrosis in chronic liver disease. We have ex-
amined the clinical usefulness of these serum markers in chronic liver disease. Serum lev-
els of prolyl 4-hydroxylase were elevated in relation to increases in liver enzyme activity， 
suggesting that serum prolyl 4-hydroxylase reflects the actual change in hepatic collagen 
biosynthesis. We developed the assay for serum lysyl oxidase activity through the partial 
purification the enzyme by a DEAE procedure in the presence of 6M urea and the follow-
ing dialysis against 3M KSCN. Serum lysyl oxidase activity was increased with the develop-
ment of histological liver fibrosis， indicating that serum lysyl oxidase is a sensitive indica帽
tor of liver fibrosis. Serum collagenase activity in chronic liver disease was lower than in 
the normal control， and decreased as liver disease developed. In contrast， serum level of 
the metalloproteinase tissue inhibitor was inversely correlated with serum collagenase ac・
tivity， indicating that serum col1agenase does not reflect the amount of collagenase in hu-
man fibrotic liver. Since the early stage of liver fibrosis is characterized by a relative larg-
er increase in type il collagen， strong interest has been raised for type il (PillNP)than 
for type 1 collagen propeptides(PICP). Serum PillNP level was increased in chronic ac-
tive liver disease， and was correlated with histological features of necrosis and inflamma-
tion rather than fibrosis. Serum PillNP should be regarded as a marker of ongoing fibro-
genesis in liver. Serum levels of the fragments of type N collagen such as 7S domain， 
TH domain and NCl domain were increased in chronic liver disease， these levels being cor“ 
related with the histological degree of liver fibrosis. Type N col1agen fragments are 
regarded as markers of basement membrane formation and sinusoids capillarization. The 
serial determination of these parameters and the combination of some parameters may help 
to evaluate the ongoing collagen metabolism in chronic liver disease. 
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No Control No CPH No CAH No 
PH (ng/mQ) 30 56土9 22 6:t 19 25 71土18
LO (dpm/mQ) 14 46:t 17 9 75土36 9 201:t 59 21 
MMP-1 (U/l) 24 62士12 10 39:t 1 12 31 :t8 15 
TIMP (ng/mQ) 25 159:t29 40 174:t40 50 200土46 42 
PIIINP (U / mQ) 25 O. 48:t0. 06 40 0.89土0.33 50 1.10:t0.35 42 
PICP (ng/mQ) 20 125士38 2 108:t35 24 107:t3 25 
7S-C (ng/mQ) 25 4. 4:t0. 7 40 6.0:t1.2 50 8.2土2.1 42 
IV-C (ng/mQ) 25 82:t18 30 95土29 41 144:t49 30 
Mean :tSD 
CPH chronic persistent hepatitis 
CAH chronic active hepatitis 
LC liver cirrhosis 
PH prolyl 4-hydroxylase 
LO lysyl oxidase 
MMP-1: collagenase 
TIMP tissue inhibitor of metalloproteinase 
PIIINP aminoterminal peptide of type国 procollagen
PICP carboxyterminal peptide of type N collagen 
7S-C 7S fragment of type N collagen 
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